NCT00940589View on ClinicalTrials.gov

Efficacy of Circadin® 2 mg in Patients With Mild to Moderate Alzheimer Disease Treated With AChE Inhibitor

PHASE2CompletedINTERVENTIONAL
Enrollment

73

Participants

Timeline

Start Date

September 30, 2009

Primary Completion Date

February 28, 2013

Study Completion Date

May 31, 2013

Conditions
Alzheimer's DiseaseSleep Disorder
Interventions
DRUG

Circadin

Prolonged Release melatonin (Circadin) 2mg tablets

DRUG

Placebo

Matched placebo tablets, with identical features to the Circadin tablets

Trial Locations (6)

18503

Scranton Medical Institute, Scranton

33709

Meridien Research, St. Petersburg

34601

Meridien Research, Brooksville

07856

Exodon LLC, Mount Arlington

Unknown

Merchav clinics, Tel Aviv

G20 0XA

CPS Research, Glasgow

Sponsors
All Listed Sponsors
lead

Neurim Pharmaceuticals Ltd.

INDUSTRY

NCT00940589 - Efficacy of Circadin® 2 mg in Patients With Mild to Moderate Alzheimer Disease Treated With AChE Inhibitor | Biotech Hunter | Biotech Hunter